A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Dova Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Acne Vulgaris

Treatments: Drug: Low Strength IDP-107; Drug: Placebo Comparator; Drug: High Strength IDP-107

Study type: Interventional

Funder types: Industry

Identifiers

NCT00666900

DPSI-IDP-107-P2-01

Details and patient eligibility

About

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Enrollment: 366 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

• Dermatological conditions of the face that could interfere with clinical evaluations
• Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

366 participants in 3 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: Low Strength IDP-107

2

Experimental group

Treatment:

Drug: High Strength IDP-107

3

Placebo Comparator group

Treatment:

Drug: Placebo Comparator